Results 1,261-1,280 of 4,002 for speaker:Rose Conway Walsh

Seanad: Irish Human Rights and Equality Commission (Gender Pay Gap Information) Bill: Committee Stage (25 Oct 2017)

Rose Conway Walsh: No. I will not do so, but I reserve the right to present the amendment again. I will call a vote on it on Report Stage. I thank the Labour Party for presenting the Bill which has 100% support from us it, but we strongly believe the issues outlined in the amendments need to be dealt with in the Bill.

Seanad: Irish Human Rights and Equality Commission (Gender Pay Gap Information) Bill: Committee Stage (25 Oct 2017)

Rose Conway Walsh: Yes. I will re-enter it with amendments Nos. 2 and 3 on Report Stage.

Seanad: Irish Human Rights and Equality Commission (Gender Pay Gap Information) Bill: Committee Stage (25 Oct 2017)

Rose Conway Walsh: I move amendment No. 4:In page 4, line 22, after “class A fine.” to insert the following:“Those deemed to be repeatedly in breach of the provisions contained within a scheme may be subject to multiple class A fines; with the name of the company being added to a public database of repeat offenders.”. This amendment would make repeat offenders subject to multiple...

Seanad: Order of Business (26 Oct 2017)

Rose Conway Walsh: I know my colleagues on the right will welcome the Minister, Deputy Regina Doherty, coming into the House to tease out some of the issues around JobPath and to evaluate whether the €350 million being spent on it and the €17 million that was spent on it last year is justified. I look forward to that debate and I hope it happens sooner rather than later. A word that I know this...

Seanad: Order of Business (8 Nov 2017)

Rose Conway Walsh: I rise today to address the issue of tax avoidance once again, particularly in light of the Paradise - or parasite - Papers. This is not a new phenomenon. I was absolutely amazed last night to hear a Fianna Fáil Deputy state that he could not say whether Fianna Fáil supported Apple in respect of the €13.5 billion it has been asked to return to the State to put into an...

Seanad: Order of Business (8 Nov 2017)

Rose Conway Walsh: Fianna Fáil then told the company that took them from us that it did not have to pay tax for at least 20 years, just as the banks have been told now. People in County Mayo and rural Ireland who listened to that would ask what in the name of God is going on in terms of our natural resources and the tax avoidance. It is very clear from the Paradise Papers that the golden circle is...

Seanad: Order of Business (8 Nov 2017)

Rose Conway Walsh: It would be good to have a debate on the issue.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: I will take 15 minutes and Deputy Gino Kenny will be well back.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: I have a series of short questions and I am confining them to Translarna. I need the answers to certain ones in order to be able to tease out some of the things that were being said. Is that okay?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: On Translarna, I want to take it in three parts. First, I want to take it in relation to the FDA and what has been said so far. Then I want to take it on the cost specifically and on the data issue. In terms of the FDA and the witnesses' reference to non-approval in the US, is it true that most orphan drugs that are put before the FDA are not approved in the first instance? Is it the...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: So it is not true to say that most applications for orphan drugs through the FDA are refused in the first instance.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: I am just trying to get at how much weight the FDA carries in terms of our approval.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: So it is not an automatic process for here.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: Okay, that is fair enough. So really the EMA is the body that would carry more weight because obviously that is within Europe and we are all part of Europe. I just want to get at conditional approval. Is it not true to say that most orphan drugs that go through the EMA get conditional approval rather than full approval merely because they are new drugs that are being introduced and then...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: There are actually 400 children across the EU on Translarna. Eighteen of the 22 countries with approval are within the EU. Can the witness confirm that?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: The witness does not know how many children in the EU are using this drug.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: I completely understand that, but we do not operate in a vacuum in terms of EMA, and that has to be taken on board.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: Do we approve orphan drugs on a conditional basis? Have we done that for any other drugs? I ask these questions in the context of the situation Lewis Harte-Walsh from Castlebar finds himself in. He was six last Thursday and he desperately needs Translarna so that he can continue to walk. We are talking about two boys in the whole of the State who need this drug now. We need to bear that...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: Perhaps we can examine how the decision was made, because I know it was rejected on the grounds of cost and of data. On the cost that has been quoted, as opposed to the real cost, I want to know how much negotiation was done with the drug company to come to an agreement on a reasonable price. I understand the figure quoted by Professor Barry is based on a ten year old boy because Translarna...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Rose Conway Walsh: I understand that.